FX.co ★ GlucoTrack Drops 24% Despite Successful First-in-Human Study Of CGM

GlucoTrack, Inc. (GCTK) experienced a notable decline of 24.56% in its stock price during Tuesday's trading session, following the announcement of having successfully completed a first-in-human study for its continuous glucose monitor (CGM).

As of now, GCTK shares are being traded at $0.86, marking a decrease of $0.17 from the previous closing price of $1.14. Throughout the day's trading, the stock has shown significant volatility, reaching a peak of $2.13 and dipping to a low of $0.89. The trading volume has dramatically increased to 43.61 million shares, significantly surpassing the daily average volume of 2.35 million shares. Over the past 52 weeks, the stock has ranged from $0.89 to $99.00.

GlucoTrack's innovative device, which accurately measures glucose levels through a blood vessel, is implanted in the subclavian vein beneath the collarbone. Notably, it does not necessitate an external on-body component.

While effective, GlucoTrack highlights that conventional subcutaneous CGMs still present certain drawbacks.